Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Tuberculosis Therapeutics Market

Tuberculosis Therapeutics Market Share

Report ID: GMI10113
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Tuberculosis Therapeutics Market Share

The Tuberculosis therapeutics industry is competitive in nature, with various large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel therapeutics with improved efficiency and cost-effectiveness are key market strategies for Tuberculosis therapeutics, drugs manufacturers, driving competition and innovation in the industry. This emphasis on innovation aims to address evolving clinical needs and enhance patient outcomes, positioning companies to gain market share and meet the growing demand for novel Tuberculosis therapeutics.

Tuberculosis Therapeutics Market Companies

Some of the eminent market participants operating in the Tuberculosis therapeutics industry include:

Aventis Pharmaceuticals Limited
Bayer Health Care
Eli Lilly And Company
Johnson & Johnson Services; Inc.
Lupin
Macleods Pharmaceuticals Ltd.
Mylan N.V.
Otsuka Pharmaceutical Co., Ltd.
Pfizer Inc.
Sanofi

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global tuberculosis therapeutics market size was valued at USD 2 billion in 2023 and is estimated to grow at 4.1% CAGR from 2024 to 2032, driven by the rising prevalence of Tuberculosis.

The active tuberculosis (TB) therapeutics segment of the market held 88.8% share in 2023 and will expand rapidly through 2032, as it requires immediate and effective treatment to prevent the spread of the disease.

North America tuberculosis therapeutics market size was USD 642.6 million in 2023 and is predicted to witness substantial market growth through 2032, driven by robust public health programs and initiatives by government agencies.

Lupin, Macleods Pharmaceuticals Ltd, Mylan N.V, Otsuka Pharmaceutical Co., Ltd, Pfizer Inc, and Sanofi, among others.